Literature DB >> 11896472

Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction.

J D Brioni1, M Nakane, G C Hsieh, R B Moreland, T Kolasa, J P Sullivan.   

Abstract

Soluble guanylate cyclase (sGC) is an important enzyme in corpus cavernosum smooth muscle cells as it is one of the regulators of the synthesis of cGMP. The efficacy of sildenafil (Viagra) in the treatment of male erectile dysfunction indicates the importance of the cGMP system in the erectile response as the increased levels of cGMP induce relaxation of the corpus cavernosum. sGC is physiologically activated by nitric oxide (NO) during sexual stimulation, and its activity can be pharmacologically enhanced by several NO-donors. Agents like YC-1 can also activate sGC after binding to a novel allosteric site in the enzyme, a site different from the NO binding site. YC-1 can relax rabbit cavernosal tissue and it facilitates penile erection in vivo. This review summarizes the enzymology, biochemistry and pharmacology of this novel allosteric site and its relevance for the regulation of penile function. This type of sGC activators represent a new class of compounds with a different pharmacological profile in comparison to the classical NO-donors and they could be beneficial for the treatment of male erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896472     DOI: 10.1038/sj.ijir.3900801

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  14 in total

1.  Current Diagnosis and Management of Erectile Dysfunction.

Authors:  Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2014-09

Review 2.  In vitro models: research in physiology and pharmacology of the lower urinary tract.

Authors:  Robert B Moreland
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

3.  Hemodynamic effects of sildenafil citrate (Viagra) on segmental branches of bilateral renal arteries.

Authors:  Arslan Ardicoglu; Ercan Kocakoc; Veysel Yuzgec; Zulkif Bozgeyik; Halit Canatan; Adem Kiris
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

4.  In vitro and in vivo studies on the importance of the soluble guanylyl cyclase α1 subunit in penile erection.

Authors:  Kelly Decaluwé; Sofie Nimmegeers; Robrecht Thoonen; Emanuel Buys; Peter Brouckaert; Johan Van de Voorde
Journal:  World J Urol       Date:  2010-01-23       Impact factor: 4.226

Review 5.  The future is today: emerging drugs for the treatment of erectile dysfunction.

Authors:  Maarten Albersen; Alan W Shindel; Kuwong B Mwamukonda; Tom F Lue
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

6.  Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats.

Authors:  Jorge D Brioni; Robert B Moreland; Marlon Cowart; Gin C Hsieh; Andrew O Stewart; Petter Hedlund; Diana L Donnelly-Roberts; Masaki Nakane; James J Lynch; Teodozyi Kolasa; James S Polakowski; Mark A Osinski; Kennan Marsh; Karl-Erik Andersson; James P Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-15       Impact factor: 11.205

7.  A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.

Authors:  George F Lasker; Jason H Maley; Philip J Kadowitz
Journal:  Adv Pharmacol Sci       Date:  2010

8.  [Therapy of erectile dysfunction in 2005].

Authors:  H Porst
Journal:  Urologe A       Date:  2003-10       Impact factor: 0.639

Review 9.  Looking to the future for erectile dysfunction therapies.

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Chuanxiongzine relaxes isolated corpus cavernosum strips and raises intracavernous pressure in rabbits.

Authors:  H-J Xiao; T Wang; J Chen; L-C Fan; C-P Yin; J-H Liu; X Gao
Journal:  Int J Impot Res       Date:  2009-11-26       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.